Cara Therapeutics effects 1-for-12 reverse stock split and reduces authorized shares from 200M to ~16.7M

Tvardi Therapeutics, Inc.

Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.
Authorized common shares reduced from 200,000,000 to 16,666,667; par value unchanged.
No fractional shares issued; cash payment will be made in lieu of fractional shares.
Proportionate adjustments made to stock options, equity plan reserves, and exercise prices.
Stockholder-approved at June 4, 2024 annual meeting; board approved specific ratio Dec 19, 2024.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Tvardi Therapeutics, Inc.: Amendment of Amended and Restated Certificate of Incorporation to effect a one-for-twelve reverse stock split and reduction in authorized shares from 200,000,000 to 16,666,667 (effective 2024-12-30).

Change: charter amendment
Effective: 2024-12-30

Exact text from the filing

On December 30, 2024, Cara Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 (the “ Shares Reduction ”).

View on SEC.gov

Browse all governance changes →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-132481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.